Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
Clinical trial NCT02268409 · COMPLETED
Trial details
- NCT number
- NCT02268409
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-20
- Primary completion
- 2020-06-18
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.